The Japan Diabetes Society

JapaneseEnglish

Vol.12 - No.4 (October 2021)

Vol.12 - No.4 (October 2021)

REVIEW ARTICLES

ORIGINAL ARTICLES

Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a real-world multicenter trial
F. Sawano, N. Kamei, M. Miyahara, K. Kobuke, S. Nakanishi, C. Nagano, H. Nojima, S. Maeda, H. Watanabe, R. Kishimoto, M. Yamashita, A. Hamaoka, K. Mukai, T. Tsuboi, H. Mochizuki, R. Nakashima, Y. Sakashita, H. Morishita, T. Kitamura 364-378
Determinants of type 2 diabetes remission after bariatric surgery in obese Japanese patients: a retrospective cohort study
M. Ohira, Y. Watanabe, T. Yamaguchi, A. Saiki, S. Nakamura, S. Tanaka, N. Shimizu, T. Nabekura, T. Oshiro, I. Tatsuno 379-388
Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro
L. Yamamoto, S. Yamashita, T. Nomiyama, T. Kawanami, Y. Hamaguchi, T. Shigeoka, T. Horikawa, Y. Tanaka, T. Yanase, D. Kawanami, A. Iwasaki 389-398
Diabetes-related acute metabolic emergencies in COVID-19 patients: a systematic review and meta-analysis
V.P. Papadopoulos, Marios-Vasileios Koutroulos, Dimitra-Georgia Zikoudi, Stefania-Aspasia Bakola, P. Avramidou, N. Touzlatzi, D.K. Filippou 445-459

CASE REPORTS

Clinical features resembling subcutaneous insulin resistance observed in a patient with type 2 diabetes and severe COVID-19-associated pneumonia: a case report
A. Satomura, Y. Oikawa, S. Nakanishi, S. Takagi, G. Mizutani, S. Iida, H. Nakayama, Y. Haga, M. Nagata, S. Maesaki, T. Mimura, A. Shimada 474-479

Update: October 11, 2021

SUB MENU